Comparison of Single Trough-based Area Under the Concentration-time Curve Versus Trough Concentration for the Incidence of Vancomycin-associated Nephrotoxicity
Overview
Microbiology
Pharmacology
Authors
Affiliations
Introduction: While the revised 2020 consensus guideline recommends the use of area under the concentration-time curve (AUC)-guided vancomycin monitoring, collecting multiple vancomycin serum samples to calculate the AUC may cause clinical complications. The aim of the present retrospective study was to evaluate whether AUC-guided vancomycin monitoring, in which AUC was calculated based on a single trough concentration, is a better predictor of nephrotoxicity than trough-guided monitoring in patients receiving vancomycin therapy.
Methods: A single-center, retrospective cohort study was conducted at the 614-bed Gifu University Hospital in Japan. Patients who received intravenous vancomycin for a documented or suspected infection and had their serum vancomycin trough concentration monitored between October 1, 2016 and September 30, 2020 were enrolled in the present study.
Results: Multivariate Cox proportional hazard analysis indicated that AUC (>600 μg•h/mL) was a significant risk factor for the incidence of acute kidney injury (AKI), while trough concentration (≥15 μg/mL) was not. Moreover, the AUC (>600 μg•h/mL) showed higher specificity and similar sensitivity to the trough concentration (≥15 μg/mL). Kaplan-Meier plots of the cumulative incidence of the AKI-free rate in patients indicated that the onset of AKI was significantly longer in patients with AUC ≤600 μg•h/mL than in patients with AUC >600 μg•h/mL (HR, 16.1; 95% CI, 6.3-41.2; p < 0.001).
Conclusion: AUC based on a single trough concentration was a better predictor of nephrotoxicity than trough concentration.
Nakazono K, Saito H, Ohkubo A, Onodera H, Wakatake H, Katsuta Y IDCases. 2024; 37:e02035.
PMID: 39155945 PMC: 11326916. DOI: 10.1016/j.idcr.2024.e02035.
Wong S, Selby P, Reuter S Pharmacol Res Perspect. 2024; 12(4):e1231.
PMID: 38940223 PMC: 11211924. DOI: 10.1002/prp2.1231.
Ishigo T, Matsumoto K, Yoshida H, Tanaka H, Ibe Y, Fujii S Microbiol Spectr. 2024; 12(7):e0373923.
PMID: 38775483 PMC: 11324017. DOI: 10.1128/spectrum.03739-23.
Patil T, Zysk S, Akridge M, McCraven R, Vasudeva S J Pharm Technol. 2023; 39(3):123-133.
PMID: 37323768 PMC: 10268043. DOI: 10.1177/87551225231172349.
Jantarathaneewat K, Phodha T, Singhasenee K, Katawethiwong P, Suwantarat N, Camins B Antibiotics (Basel). 2023; 12(2).
PMID: 36830284 PMC: 9952732. DOI: 10.3390/antibiotics12020374.